Jason Kelly, Ginkgo Bioworks CEO (Kyle Grillot/Bloomberg via Getty Images)

Af­ter Ko­dak de­ba­cle, US lends $1.1B to a syn­thet­ic bi­ol­o­gy com­pa­ny and their big Covid-19, mR­NA plans

In mid-Au­gust, as Ko­dak’s $765 mil­lion gov­ern­ment-backed push in­to drug man­u­fac­tur­ing slow­ly fell apart in na­tion­al head­lines, Gink­go Bioworks CEO …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.